




RealRate

PHARMACEUTICAL 2014

Cymabay Therapeutics Inc
Rank 124 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cymbay Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cymbay Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Cymbay Therapeutics Inc is the variable Liabilities, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 254%, being 11% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	32,239
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,488
Liabilities, Non-Current	9.0
Other Assets	258
Other Compr. Net Income	2.0
Other Expenses	822
Other Liabilities	4,407
Other Net Income	145
Other Revenues	0
Property and Equipment	3.0
Research and Development	4,525
Selling, General and Administrative Expense	4,871

Output Variable	Value in 1000 USD
Assets	32,500
Liabilities	13,904
Expenses	10,218
Revenues	0
Stockholders Equity	18,596
Net Income	-10,073
Comprehensive Net Income	-10,072
BaseVar	28,384
ECR before Limited Liability	131%
Economic Capital Ratio	254%